Please login to the form below

Not currently logged in
Email:
Password:

Horizon appoints board chair

Dr Ian Gilham assumes position full-time
Horizon Ian Gilham

Horizon Discovery has appointed Dr Ian Gilham as chairman of its board of directors on a permanent basis after he spent several months as its interim chairman.

The UK-based genetic research firm will look to benefit from Dr Gilham's thirty years of industry experience, which includes his role as CEO of in vitro diagnostics company Axis-Shield.

He held this role until from 2008 to 2011, when the company was acquired by Alere.

Dr Gilham's prior experience also includes senior positions at leading pharma companies, such as GlaxoSmithKline and Abbott Labs.

Horizon's CEO Dr Darrin Disley said: “As interim chairman [Dr Gilham] has made an invaluable contribution to the growth and success of the Company and we look forward to benefitting from his guidance as Horizon continues to develop as a world-leading translational genomics organisation."

These growth prospects include a partnership with AstraZeneca to research personalised treatments in oncology.

17th January 2014

From: Research

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics